



UK Health  
Security  
Agency

# Public Health Microbiology Division

## Virus Reference Department (VRD) User manual

Version 20, July 2024, Q-Pulse VW0405

# Contents

Public Health Microbiology Division .....	1
Contents.....	2
Foreword.....	3
Disclaimer .....	4
Amendment history .....	4
Establishment of service agreement .....	5
Key personnel and contact details .....	5
How to obtain services.....	6
Key factors affecting tests .....	11
Services available .....	14
Turnaround times.....	14
Reports .....	28
Policy on emailing reports .....	28
Quality assurance in VRD .....	28
Complaints .....	29
Public Health Microbiology: recognition of Caldicott recommendations .....	30
Compliance with the Human Tissue Act: submitting tissue samples from deceased people .....	31
Unit information.....	32
About the UK Health Security Agency .....	39

# Foreword

The UK Health Security Agency (UKHSA) Virus Reference Department (VRD) is a national and international reference centre for a wide range of virus infections. We receive clinical samples and viral isolates from public health departments, National Health Service and commercial laboratories across the UK and internationally for specialist testing, virus characterisation and susceptibility testing.

The department is made up of 8 units, including the Respiratory Virus Unit, which includes the UK World Health Organization (WHO) National Influenza Laboratory; the Enteric Virus Unit; Polio Reference Services, which includes the national WHO Global Poliovirus Network Laboratory; the Immunisation and Diagnosis Unit, which includes the WHO Global specialised Measles and Rubella Reference Laboratory; the Antiviral Unit, which includes a WHO Global Specialised human immunodeficiency virus (HIV) Drug Resistance Laboratory; and the Clinical Services Unit, which is listed as a WHO pre-qualification evaluation laboratory. VRD also houses the Blood Borne Virus Unit with NHS Blood and Transplant, providing reference services for hepatitis viruses and other risks to blood supply, and the Human Papillomavirus Unit (HPV Unit) which carries out surveillance and vaccine studies. The department has links with the High Containment Microbiology (HCM) department, which houses a containment level 4 (CL4) laboratory.

Members of VRD staff sit on a number of national and international panels and provide advice to the WHO, FSA, Department of Health and Social Care, the European Union and ECDC, and provide assistance and advice in national and international outbreak investigations. The main focus of the laboratory's work is to provide national reference and specialist diagnostic services. The expertise developed through the provision of this reference service supports a substantial applied research and development programme. We also provide support for outbreak investigations in the UK and internationally. VRD was involved in the development and evaluation of oral fluid and dried blood spot testing for HIV, hepatitis viruses, measles, mumps and rubella. The resultant national diagnostic service offered to primary care plays an important role in monitoring vaccine programmes and infection in hard-to-reach groups.

The WHO Measles and Rubella Laboratory has established 2 web-reportable sequence databases which are used by the WHO laboratory network. The WHO National Influenza Laboratory has been involved in establishing the national influenza diagnostic network and has played a key role in the investigation of avian influenza outbreaks and influenza pandemics, including the development of diagnostic tests and vaccine evaluation. Currently the focus is on responding to emerging novel viruses, such as SARS-CoV-2 and MERS, and in a wide-ranging programme assessing the value of whole genome sequencing for public health virology. The user manual is published on GOV.UK [Virus reference department \(VRD\)](#) and emailed directly to our service users and we welcome any feedback to enable us to improve the service.

## Disclaimer

This document has been controlled under the UKHSA Document Control System. Any printed copy becomes an uncontrolled document. It is the responsibility of the copy holder to ensure that any hard copy or locally held copy in their possession reflects the current version available from the UKHSA GOV.UK internet site.

## Amendment history

Version no.	Date	Sections affected	Pages affected
14	August 2018	Key factors affecting tests. Services available. Polio Reference Service information. Contact details.	All
15	November 2019	Terms and conditions of business. Forensic test information. Key information about tests. Changes to C. trachnomatis/LGV. Polyomavirus and syphilis testing. Quality assurance information. Compliance with HTA. Contact details.	5, 9, 10 to 12, 21, 24, 26, 29, 32, 33 to 40
16	May 2021	Significant update of all sections.	All
17	August 2022	Updates to all sections following transition from Public Health England (PHE) to UKHSA	All
18	July 2023	Addition of Public Health Microbiology Division, update A-Z listing and staff list	All
19	June 2024	ISO 15189:2022, Referral External Laboratories, New interim Deputy Director, Confidentiality, Oral request, Consent, Establishment of service agreement, Haemophilus ducreyi, Treponema (syphilis), Lymphogranuloma venereum (LGV removed from list, service transferred to STIRL.	All
20	July 2024	ISO 15189:2022, the requirement for documented confirmation of oral requests within a specified timeframe, Lists of workflows with corresponding accreditation status are available upon request on a confidential basis	9, 29

## Establishment of service agreement

Each request accepted by the laboratory for examination is considered to be an agreement under UKHSA terms and conditions of business [Terms and conditions for the supply of goods and/or services](#). Specific requests for service level agreements or contracts should be made to [business@ukhsa.gov.uk](mailto:business@ukhsa.gov.uk)

## Key personnel and contact details

Name	Designation	Email	Telephone
Derren Ready	Deputy Director, Public Health Microbiology Division (interim)	<a href="mailto:derren.ready@ukhsa.gov.uk">derren.ready@ukhsa.gov.uk</a>	020 8327 6146
Hemanti Patel	Head of Laboratory Scientific Services	<a href="mailto:hemanti.patel@ukhsa.gov.uk">hemanti.patel@ukhsa.gov.uk</a>	020 8327 7705
Sunita Gurung	Head of Business and Commercial Services (interim)	<a href="mailto:sunita.gurung@ukhsa.gov.uk">sunita.gurung@ukhsa.gov.uk</a>	020 8327 6758

Full contact details for VRD staff members may be found from page 48 onwards.

UKHSA Public Health Microbiology switchboard: 020 8200 4400

VRD General Office:

Telephone: 020 83277887 staffed 9am to 5pm Monday to Friday

email: [vrqueries@ukhsa.gov.uk](mailto:vrqueries@ukhsa.gov.uk)

### DX address

UKHSA Colindale  
Virology  
DX 6530002

### Postal address

UK Health Security Agency  
Virus Reference Department  
61 Colindale Avenue  
London NW9 5EQ

# How to obtain services

## Hours of service

The Department is open from 9 am to 5 pm, Monday to Friday. Telephone enquiries via the VRD general office are available from 9 am to 5 pm, Monday to Friday. No routine services are available outside these hours. The Department is closed on public holidays.

A 24-hour service is available for the urgent diagnosis of viral haemorrhagic fever (VHFs) and smallpox through the Imported Fever Service (IFS). Hospital doctors can contact the IFS, after discussion with their local infection service consultant (microbiology, virology or infectious diseases), via 0844 778 8990.

## Services to the public

VRD does not offer diagnostic services to members of the public except via a registered medical practitioner. Results can only be issued to the requesting physician or medical unit and will not be given to patients directly under any circumstance. We reserve the right to check the authenticity of callers in order to protect the confidentiality of patients' personal data. There are no clinical facilities at UKHSA Colindale and we are unable to see patients or give telephone medical advice directly to members of the public.

## Specimen submission guidelines

### Specimens

All specimens must be labelled with:

- surname, forename or other unique patient identifier
- date of birth
- sender's sample number
- date of collection of specimen

Printed specimen labels should be used wherever possible. Please note that unlabelled specimens cannot be processed and may be discarded.

## Request forms

VRD specific request forms are available from the UKHSA [Virus Reference Department \(VRD\)](#) webpages. Certain forms are available via hyperlinks from the [A to Z list of tests available](#) pages. Guidelines for the completion of forms may also be found on the UKHSA [Virus Reference Department \(VRD\)](#) webpages.

Users must use these forms for all requests and to complete them with the details below. Please check the web site using the link above for the most up to date request form prior to completing the form. Failure to use these forms may lead to delays in specimen turnaround time.

Forms must match the information on the sample. Any specimens where there is a mismatch between data on the sample and on the request form may be rejected. If multiple samples are to be sent for the same patient with the same reference number then a unique identifier must be included on the sample and the request form to differentiate between each sample.

### Forms must include the following information

Tests required:

- specimen type and site where appropriate
- hazard group, if known or suspected to contain Hazard Group 3 pathogens (special arrangements apply for specimens suspected of harbouring hazard group 4 agents – see page 35)
- date of collection
- sender's sample number
- contact information of requester (vital for urgent requests)

Request forms should also have:

- date of dispatch
- sex
- relevant clinical information including details of any antiviral therapy
- date of onset
- vaccination history
- NHS number
- reference to any previous VRD reports (please give VRD laboratory number if known)
- for investigations of maternal transmission, please identify the linked mother or child

Please complete the forms in black ink (not red or any other colour) as forms are scanned electronically.

Failure to comply with our specimen submission guidelines may lead to specimen rejection and/or delay of reports.

## Request for additional tests

All samples sent in for testing in VRD must be accompanied by a completed request form in the first instance. If additional laboratory testing is required on a sample previously submitted to VRD, please contact the relevant unit directly. Original specimens are normally retained for at least one month but further testing may not be possible due to sample volume constraints, specimen viability or other factors. The unit will be able to advise on the feasibility of using the original specimen for analysis.

Units may, at their own discretion, accept oral (verbal) requests for additional testing for samples already received. Written confirmation of your request must be sent to the unit prior to the release of results and should be received within 48 hours of the verbal request. Written confirmation may be sent via email (by attaching a scanned request form) or in the post. Email communications should be between the same domains to ensure security of information. Requests for additional testing must only be made via a registered medical practitioner or HCPC registered biomedical or clinical scientist. Please note there are no fax facilities at UKHSA Colindale.

## Specimen quarantine policy

Failure to complete relevant information on the request form may lead to the specimen being placed in quarantine on arrival at UKHSA, and subsequent delays in processing whilst further information is sought from the referring laboratory. Please ensure all relevant clinical information is completed on the form(s).

Specimens may also be quarantined if there is evidence the patient has visited an endemic area for high-risk pathogens, or an area where there is known to be a recent or current outbreak of a high-risk pathogen.

In the event of a specimen being quarantined, the referring laboratory will be contacted to provide further information. Where no response is received and hence no testing is performed, the samples will be kept for a minimum of one month, after which they may be discarded.

## Urgent specimen

If a reference service is required urgently, please contact a senior staff from the relevant unit to discuss prior to dispatch. Always mark 'urgent' clearly on the request form.



## Forensic and medico-legal specimens

The department has capabilities to test medico-legal specimens and certain types of forensic specimens. However, whilst most assays performed are accredited under ISO15189:2022 for diagnostic purposes, the department is not accredited for performing these tests for forensic work where the results of the sample will go into the criminal justice system.

Due to the legal requirements pertaining to these types of specimens, they will only be processed if the department has been contacted in advance and if all paperwork (including the chain of evidence form) is correctly completed. This will enable the department to ensure continuity of evidence throughout testing.

All requests for forensic tests must be discussed with the relevant units prior to sending the specimen to the laboratory.

## Specimen transportation

Specimens sent by post or by courier must be in a sealed container, surrounded by sufficient absorbent packing material to take up any leakage in the event of damage during transit, sealed in a plastic bag and placed in an approved outer container which meets current postal or other transport regulations. Contact the departmental Safety Manager ([Lauren Woodman](#) on 020 8327 7603) or the Virology Specimen Reception manager ([Fiona Clode](#) on 020 8327 7129 or 020 8327 6063) for further information.

Special arrangements are required for the collection and transportation of specimens involving suspected hazard group 4 agents. See page 35 for further details.

UKHSA follows the [Guidance on regulations for the transport of infectious substances 2021-2022](#), published by the WHO. Specimens sent to VRD laboratories must meet the criteria in these guidelines. Samples which are not packaged appropriately may not be processed.

Arrangements must be made by referring laboratories to ensure that time and temperature requirements (detailed under Key factors affecting tests, below) for sample transportation are maintained. Failure to achieve this may compromise sample integrity and the validity of test results. Samples which do not meet the sample acceptance criteria may not be processed. When sample integrity is compromised and the safety of the carrier or the general public is placed at risk, the organization responsible for the transport of the sample shall be notified immediately and measures would be taken to mitigate the risk and to avoid recurrence.

Samples which are dispatched at ambient temperature (10°C to 25°C) must have a transit time of no more than 72 hours. If the date of receipt is greater than 72 hours from the date of dispatch, the referring laboratory will be informed and the specimens may not be processed.

Please do not include confidential letters within specimen boxes which are not related to the specimens. These should be sent separately and should be clearly marked for the attention of the addressee only.

## Consent

Senders must obtain informed consent from patients for all samples referred to VRD. VRD will select an appropriate panel of tests based on the information provided and perform assays relevant to the best interest of the patient. VRD does not require separate consent documentation to be sent, provided the sample is sent by a recognised service user. Samples received directly from patients cannot be processed unless also requested by an appropriate medical professional.

# Key factors affecting tests

## Serology tests

Samples which are highly haemolysed, hyperlipaemic or which contain microbial contamination should not be sent. Heat inactivated samples may give rise to erroneous results in a number of assays and should not be sent – please contact the relevant unit prior to sending the specimen if no other sample is available. Serum or plasma samples should be stored at 2 to 8°C for no longer than 7 days – if stored for a longer period of time, they should be frozen at minus 20°C or lower. Repeated freeze-thaw cycles should be avoided, as this may degrade the analyte sought and cause inaccurate quantitation or false negative results. If sending samples at ambient temperature, transit time must be less than 72 hours. Please note that while post-mortem samples may be accepted, only a limited number of tests available from VRD laboratories have been evaluated for use with samples from cadavers.

Certain assays (for example, polyomavirus serology assays, avian Influenza antibody testing) require serum only – plasma samples are not suitable. Specific requirements are listed from [page 16 onwards](#). When sending paired sera, please ensure samples are taken at least 14 days apart.

## Molecular tests

EDTA plasma is preferable to serum, as degradation of nucleic acid can occur in serum/ clotted samples, which may result in under-reporting of viral load. Serum or plasma should be separated by centrifugation within 4 hours of collection. Samples should be sent as soon as possible, or frozen at minus 20°C or lower. Repeated freeze-thaw cycles (greater than 3 times) may result in under-quantification and should be avoided. Samples which are highly haemolysed, hyperlipaemic or which contain gross microbial contamination should not be sent; where this is unavoidable (for example, haemolysed samples from post-mortem specimens) the laboratory should be contacted in advance for advice. Do not send dry swabs, charcoal swabs, swabs in bacterial transport gel or swabs with wooden shafts, as all are unsuitable for molecular testing. Heparinised samples, or samples from patients who have received heparin, may give erroneous results and must not be sent – please contact laboratory for advice.

If the original specimen is not available, cDNA may be sent as an alternative – please contact the relevant unit prior to sending specimen. Details of the extraction and cDNA generation method used must be provided in such cases. Please note that unprotected RNA samples will degrade rapidly and are not suitable.

Details of any antiviral therapy should be given wherever possible.

## Whole (unseparated) blood samples

Certain tests – for example, HIV and Human T-cell lymphotropic virus (HTLV) proviral DNA – require whole unseparated blood collected on EDTA. Samples should be sent to the laboratory as soon as possible after collection. Where possible, whole blood samples should not be sent over a weekend. Samples over 3 days old may not be suitable for testing.

## Samples for poliovirus isolation testing

Faecal samples should be unadulterated and unprocessed. Ideally 2 samples collected 24 to 48 hours apart are required, with a minimum weight of 2g (preferably 8 to 10g). Samples should reach the reference laboratory within 3 days of collection; cooled or dry ice shipment is recommended but is not essential.

## CSF, oral fluid, urine and other samples

Please contact the relevant unit prior to sending these specimens, as the assays used may not have been validated for these sample types.

## Samples for electron microscopy

Swabs in liquid medium are not recommended for electron microscopy examination of skin lesions. Suitable specimens are either smears of vesicle fluid dried onto a microscope slide, a piece of crust, scabs, or a biopsy or curettage of the lesion placed in a dry sterile container. Biopsy specimens are preferable for suspected orf as virions often remain cell-associated.

## Tissue samples

Tissue samples received for PCR testing are recommended to be sent frozen. Samples received at room temperature may give rise to unreliable results, particularly for RNA viruses. Note tissue samples that require PCR for parvovirus B19, measles, mumps or rubella testing will require additional processing time to that stated for other specimen types.

## Samples for antiviral resistance testing

Tissue culture isolates are the preferred specimens for Herpes simplex virus (HSV) antiviral resistance testing. Swabs in virus transport medium (VTM) will be accepted; a fresh swab in VTM sent as soon as possible after collection will increase the likelihood of successful virus isolation and/or culture, however successful isolation cannot be guaranteed. Samples in lysis buffer may be tested for genotypic resistance but are not suitable for phenotypic resistance tests.

For HIV genotyping and/or resistance testing, plasma samples with viral loads of greater than 500 copies per ml are required.

For Hepatitis C virus (HCV) resistance testing and genotyping by whole genome sequencing, viral loads of greater than 5000 IU per ml are required. Samples for HCV genotyping with low viral loads may be tested by NS5B sequencing rather than whole genome sequencing. Details of antiviral therapy, genotype and/or subtype and viral load should be given wherever possible.

For influenza genotypic antiviral resistance testing, respiratory secretions or nose and/or throat swabs in VTM are the preferred specimens, and tissue culture isolates if available will be accepted. Details of antiviral therapy, virus type and subtype and diagnostic PCR Ct should be given wherever possible.

## Samples for influenza strain typing or phenotypic antiviral resistance

Nose and/or throat swabs in VTM are the preferred specimens, and fluid from respiratory secretions or tissue culture isolates if available will be accepted. Virus isolation (in tissue culture) is required prior to influenza virus strain typing by haemagglutination inhibition (HAI). Respiratory samples sent as soon as possible after collection will increase the likelihood of successful virus isolation, however successful recovery of virus in culture cannot be guaranteed.

## Samples for urgent measles testing

The Virus Reference Department does not offer urgent measles testing. Please contact your local Public Health Laboratory for details on where urgent measles services are offered and the sample types needed for testing. Any samples collected and sent for local urgent testing should be in addition to routine samples sent to VRD that are required for confirming all suspected cases of measles.

## Samples for SARS CoV-2 testing (COVID-19)

Nose and/or throat swabs in VTM are the preferred specimens for SARS CoV-2 RT-PCR. Please note that a post-mortem blood sample is unsuitable for SARS CoV-2 RT-PCR analysis due to the presence of inhibitors. It is suggested that a more appropriate post-mortem nose and/or throat swab be taken instead for SARS CoV-2 RT-PCR analysis.

## Services available

The department undertakes tests for the infections listed on the following pages. Key factors affecting individual tests are noted against the relevant test, including minimum sample volumes where relevant.

## Turnaround times

Turnaround times are from day of receipt to issue of reports in calendar days. The times shown are the typical turnaround times achieved by the laboratory, but may be longer or shorter depending on the availability of staff and the complexity of the investigation. For example, turnaround times may be longer outside periods of seasonal outbreaks, with testing being conducted more frequently during epidemic seasons. Turnaround times may also be extended if additional testing is required; for example, when virus typing cannot be determined by a first-line test. VRD staff are committed to the fastest possible issue of reports, consistent with accuracy, on the specimens they examine.

## A to Z list of tests available

Request forms may be downloaded for certain tests by clicking test names.

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
<b>Adenoviruses (blood)</b>				
<a href="#">Adenovirus Testing in Whole Blood</a>	Whole blood	Contact laboratory	Contact laboratory	BBVU
<b>Adenoviruses (enteric)</b>				
<a href="#">PCR</a>	Faeces (<5 days post-onset)	Contact laboratory	Contact laboratory	EVU
<b>Adenoviruses (respiratory)</b>				
<a href="#">Virus detection by PCR / sequencing</a>	Fluid from respiratory secretions, nose and throat swabs, tissue culture fluid	Contact laboratory	Contact laboratory Note: testing performed only on known PCR positive samples	RVU
<b>Astrovirus</b>				
<a href="#">RT-PCR</a>	Faeces (<5 days post-onset)	Contact laboratory	Contact laboratory	EVU
<b>Coronavirus (seasonal)</b>				
Virus detection by PCR / sequencing	Fluid from respiratory secretions, nose and throat swabs	Contact laboratory	Contact laboratory	RVU
<b>Coronavirus (SARS-CoV-1)</b>				
Contact laboratory prior to collection of samples				RVU
<b>Coronavirus (MERS-CoV)</b>				
Contact laboratory prior to collection of sample				RVU
<b>Coronavirus (SARS-CoV-2)</b>				
Surveillance and reference testing including specific studies for RT-PCR	Fluid from respiratory secretions, nose and throat swabs. Other samples such as Serum/Plasma, CSF	6 days	Contact laboratory	RVU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
	and oral fluids by prior arrangement.			
RNA sequencing	Fluid from respiratory secretions, nose and throat swabs, RNA, lysate	Contact laboratory	Contact laboratory	RVU
<b>Enteroviruses</b>				
<a href="#">RT-PCR</a> (by prior arrangement only)	Faeces, CSF, throat swab, respiratory tract secretions. Other samples by arrangement. Minimum volume: 200µL	Contact laboratory	Faeces: clinical samples tested weekly. For other samples, contact laboratory	EVU
Typing of referred positive samples	Faeces, CSF, throat swab, respiratory tract secretions. Other samples by arrangement. Minimum volume: 200µL	Contact laboratory	Contact laboratory	EVU
<b>Hepatitis A virus (HAV)</b>				
<a href="#">RNA</a>	Serum or plasma (300µL)	14 days	Weekly (Monday)	BBVU
<a href="#">Genotyping /phylogenetics</a>	Serum or plasma (300µL)	14 days	Weekly (Monday)	BBVU
<a href="#">Anti-HAV IgG / IgM</a>	Serum or plasma (200µL)	8 days	2-3 times weekly	CSU
<b>Hepatitis B virus (HBV)</b>				
<a href="#">HBsAg detection</a>	Serum or plasma (300µL)	8 days	Every other working day	CSU
	Dried blood spots	15 days	Contact laboratory	BBVU
	Oral fluid	Contact laboratory	Contact laboratory	BBVU



Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
<a href="#">HBsAg quantification</a>	Serum or plasma (300µL)	8 days	Every other working day	CSU
HBsAg neutralisation	Serum or plasma (500µL)	15 days	Thursday	CSU
<a href="#">HBeAg</a>	Serum or plasma (300µL)	8 days	Every other working day	CSU
<a href="#">Anti-HBc</a>	Serum or plasma (300µL)	8 days	Every other working day	CSU
	Dried blood spots	15 days	Contact laboratory	BBVU
	Oral fluid	Contact laboratory	Contact laboratory	BBVU
<a href="#">Anti-HBc IgM</a>	Serum or plasma (300µL)	8 days	Every other working day	CSU
<a href="#">Anti-HBs</a>	Serum or plasma (200µL)	8 days	Every other working day	CSU
<a href="#">Anti-HBe</a>	Serum or plasma (300µL)	8 days	Every other working day	CSU
<a href="#">DNA viral load</a>	EDTA plasma (300µL)	8 days	Every other working day	CSU
<a href="#">Pre-core / BCP mutation screen</a>	EDTA plasma (300µL)	28 days	Weekly (Thursday)	BBVU
<a href="#">Surface mutation screen</a>	EDTA plasma (300µL)	28 days	Weekly (Thursday)	BBVU
<a href="#">Antiviral resistance</a>	EDTA plasma (300µL)	28 days	Weekly (Thursday)	BBVU
<a href="#">Genotyping /phylogenetics</a>	EDTA plasma (300µL)	28 days	Weekly (Thursday)	BBVU
<b>Hepatitis C virus (HCV)</b>				
<a href="#">Antibody confirmation</a>	EDTA plasma (400µL)	8 days	Weekly	CSU
HCV viral load	EDTA plasma (400µL)	8 days	Twice weekly	CSU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
Antibody confirmation (dried blood spots and oral fluid samples)	Dried blood spots Oral fluid	By special arrangement only. Contact lab for details	Contact laboratory	BBVU
Qualitative RNA detection	Dried blood spots	Contact laboratory	Contact laboratory	BBVU
Genotyping (NS5B sequencing) by special arrangement only	EDTA plasma (300µL)	Contact laboratory	Contact laboratory	CSU
	Dried blood spots	Contact laboratory	Contact laboratory	BBVU
Phylogenetics	EDTA plasma (300µL)	Contact laboratory	Contact laboratory	AVU/ BBVU
<a href="#">HCV whole genome sequencing (antiviral resistance and genotyping)</a>	EDTA plasma (preferred) or serum, >1ml RNA extracts by prior arrangement only	15 days	Weekly (Fri)	AVU
<b>Hepatitis Delta virus (HDV)</b>				
<a href="#">Anti-HDV total antibody</a>	Serum or plasma (200µL)	15 days	Weekly	CSU
<a href="#">Anti-HDV IgM</a>	Serum or plasma (200µL)	Contact laboratory	Contact laboratory	CSU
<a href="#">RNA</a>	EDTA plasma (300µL)	28 days	Weekly (Thursday)	BBVU
<b>Hepatitis E virus (HEV)</b>				
<a href="#">Anti-HEV IgG</a>	Serum or plasma (100µL)	8 days	3 times weekly	CSU
<a href="#">Anti-HEV IgM</a>	Serum or plasma (100µL)	8 days	3 times weekly	CSU
<a href="#">RNA</a>	Serum or plasma (300µL), Faeces	14 days	Weekly (Mon and Thurs)	BBVU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
<a href="#">Genotyping /phylogenetics</a>	EDTA plasma (300µL)	Contact laboratory	Contact laboratory	BBVU
<b>Herpes simplex virus (HSV 1 and 2)</b>				
<a href="#">Phenotypic drug resistance</a>	Tissue culture isolate Swab in VTM. ( <b>NB</b> : please see note regarding swabs on <a href="#">page 13</a> )	21 days 28 days	Contact laboratory	AVU AVU
<a href="#">Genotypic drug resistance</a>	Serum, plasma, CSF (200µL), swab	14 days	Contact laboratory	AVU
<a href="#">Intrathecal antibody testing</a>	Paired serum and CSF (750 µL each)	Contact laboratory	Contact laboratory	IDU
<b>HIV-1 and HIV-2</b>				
<a href="#">HIV 1 / HIV-2 antibody confirmation (excluding HIV Western blot)</a>	Serum or plasma (500µL)	8 days	Tue & Fri	CSU
<a href="#">HIV 1 / HIV-2 antibody typing</a>	Serum or plasma (500µL)	8 days	Tue, Thur	CSU
<a href="#">HIV-1 proviral DNA</a>	Unseparated blood on EDTA	8 days	Twice weekly	CSU
HIV-1 incidence testing (avidity)	Serum or plasma (200µL)	Contact laboratory	Contact laboratory	CSU
<a href="#">HIV-1 genotypic resistance</a>	EDTA plasma (>1ml)	21 days	Contact laboratory	AVU
<a href="#">HIV-1 proviral tropism testing</a>	Unseparated blood on EDTA	21 days	Contact laboratory	AVU
<a href="#">Detection of minority drug resistance mutants</a>	EDTA plasma (>1ml)	Contact laboratory	Contact laboratory	AVU
<a href="#">HIV-1 sequencing and sequence comparison</a>	EDTA plasma (>1ml)	Contact laboratory	Contact laboratory	AVU
<b>HTLV-I/II</b>				

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
<a href="#">HTLV antibody screen / confirmation / typing</a>	Serum or plasma (300µL)	8 days	Screen: 2-3 times weekly. Confirmation and typing: weekly (Tues)	CSU
<a href="#">HTLV type-specific PCR</a>	Unseparated blood on EDTA	Contact laboratory	Contact laboratory	CSU
<b>Human herpesvirus 6 (HHV-6)</b>				
<a href="#">Genotyping and confirmation of integration</a> Note: testing performed only on known PCR positive samples	CSF, serum or plasma (150µL), whole blood (500µL)	21 days	Twice per month	IDU
<b>Human herpesvirus 7 (HHV-7)</b>				
<a href="#">PCR</a>	CSF, serum or plasma (150µL), whole blood (500µL)	21 days	Twice per month	IDU
<b>Human herpesvirus 8 (HHV-8)</b>				
<a href="#">Quantitative DNA PCR</a>	Unseparated blood on EDTA. Other specimens by arrangement with laboratory	15 days	Contact laboratory	CSU
<b>Human metapneumovirus</b>				
Virus detection by multiplex PCR	Fluid from respiratory secretions, nose and throat swabs	7 days in season (Nov-Mar)	Daily in season	RVU
<b>Influenza</b>				
Virus detection by multiplex PCR	Fluid from respiratory secretions, nose and throat swabs	7 days in season (Nov-Mar)	Daily in season	RVU
Strain typing HAI	Fluid from respiratory secretions, nose and throat swabs, tissue culture fluid	Consult laboratory	2-3 runs per week in season	RVU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
Antibody response HAI	Paired acute and convalescent sera (minimum 1ml)	Consult laboratory	Consult laboratory	RVU
Influenza virus typing and drug resistance testing by Next Generation Sequencing (NGS)	Fluid from respiratory secretions, nose and throat swabs in VTM. Respiratory sample in lysis buffer	7 working days in season (October - March), 14 working days outside season (April – September)	Consult laboratory	RVU
<b>Influenza (avian)</b>				
Confirmation of regional lab H5, H7 or H9 virus detection	Respiratory sample in lysis buffer, fluid from respiratory secretions, nose and throat swabs, tissue culture fluid	24 hours	Consult laboratory	RVU
Antibody response	Paired sera (minimum 1ml)	Consult laboratory	Consult laboratory	RVU
<b>Measles</b>				
<a href="#">IgM serology for recent infection</a> Re urgent measles testing: please see note on <a href="#">page 14</a>	Serum or plasma (100µL), oral fluid (Oracol)	4 days	3x weekly	CSU
<a href="#">IgG antibody status</a>	Serum (100µL)	15 days	weekly	IDU
<a href="#">Intrathecal antibody testing</a>	Paired serum and CSF (750µL each)	Contact laboratory	Contact laboratory	IDU
<a href="#">PCR</a>	Oral fluid (Oracol), throat swabs, NPA,	10 days (Tissue: contact lab)	weekly	CSU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
	CSF (150µL), urine, tissue			
<b>MERS-CoV</b>				
Refer to coronavirus section on <a href="#">page 16</a> . Contact laboratory prior to collection of specimens.				RVU
<b>Molluscum contagiosum</b>				
<a href="#">Electron microscopy</a>	Suitable specimens are either smears of vesicle fluid dried onto a microscope slide, or a piece of crust or biopsy of a lesion placed in a dry sterile container. Please note swabs of skin lesions in liquid media are not recommended for electron microscopy.	4 days	As required	VRD General Office
<b>Mumps</b>				
<a href="#">IgM serology for recent infection</a>	Serum or plasma (100µL) Oral fluid (Oracol)	10 days	weekly	CSU
<a href="#">IgG antibody status</a>	Serum or plasma (100µL)	10 days	weekly	CSU
<a href="#">PCR</a>	Oral fluid (Oracol), throat swabs, NPA, urine or CSF (150µL) Urine and CSF not UKAS accredited	10 days	weekly	CSU
<b>Noroviruses</b>				
<a href="#">RT-PCR</a> (by prior arrangement only)	Faeces (<5 days post-onset)	Contact laboratory	Clinical samples: tested weekly	EVU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
Genotyping of referred positive samples	Faeces (<5 days post-onset)	Contact laboratory	Contact laboratory	EVU
Environmental investigations	Contact laboratory	Contact laboratory	Contact laboratory	EVU
<b>Orf</b>				
<a href="#">Electron microscopy</a>	Biopsy specimens are preferable for suspected orf. Suitable alternative specimens are either smears of vesicle fluid dried onto a microscope slide, or a piece of crust or biopsy of the lesion placed in a dry sterile container. Please note swabs of skin lesions in liquid media are not recommended for electron microscopy.	4 days	As required	VRD General Office
<b>Parainfluenza</b>				
Virus detection by PCR / sequencing	Fluid from respiratory secretions, nose and throat swabs	Contact laboratory	Contact laboratory	RVU
<b>Parechovirus</b>				
RT-PCR	Faeces, CSF, respiratory secretions / swab, serum; other samples by arrangement. Minimum volume 200µL	Contact laboratory	Contact laboratory	EVU
Genotyping	Faeces, CSF, respiratory secretions / swab, serum; other samples by arrangement. Minimum volume 200µL	Contact laboratory	Contact laboratory	EVU

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
<b>Parvovirus B19</b>				
<a href="#">Serology (IgG/ IgM)</a>	Serum or plasma (200µL)	10 days	weekly	CSU
<a href="#">PCR</a>	Serum or plasma, amniotic fluid (150µL), placenta, foetal tissue (frozen)	10 days (Tissue: contact laboratory)	Twice weekly	IDU
<b>Polioviruses</b>				
Virus isolation and Intertypic Differentiation PCR	Unprocessed faeces (required for all AFP cases): 2 samples collected 24-48h apart, min.2g (8-10g preferred), respiratory tract specimens, CSF	14 days	Contact laboratory	PRS
<a href="#">Poliovirus serology</a>	Serum with date of collection; please refer to <a href="#">Poliomyelitis: Indications for serological testing</a>	Contact laboratory	Contact laboratory	PRS
<b>Polyomavirus JC</b>				
PCR	CSF, urine, serum, plasma (150 µL), whole blood (300 µL), tissue	10 days	Weekly	IDU
<b>Rabies exposure</b>				
Exposure advice only – contact rabies clerk on 0330 128 1020				
<b>Respiratory syncytial virus (RSV)</b>				
Virus detection by multiplex PCR	Fluid from respiratory secretions, nose and throat swabs	7 days in season (Nov-Mar)	Daily in season	RVU
<b>Rhinovirus</b>				



Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
Virus detection by PCR	Fluid from respiratory secretions, nose and throat swabs	Contact laboratory	Contact laboratory	RVU
<b>Rubella</b>				
<a href="#">IgG / IgM serology for recent infection</a>	Serum or plasma (50µL), oral fluid (Oracol)	10 days	weekly	CSU
<a href="#">IgG antibody status</a>	Serum or plasma (100µL)	10 days	weekly	CSU
<a href="#">PCR and genotyping</a>	Oral fluid (Oracol), throat swabs, NPA, urine, CSF (150µL), amniotic fluid (150µL), placenta, foetal tissue (frozen)	Contact laboratory	Contact laboratory	IDU
<a href="#">Intrathecal antibody testing</a>	Paired serum and CSF (750µL each)	Contact laboratory	Contact laboratory	IDU
<b>Rotavirus</b>				
<a href="#">RT-PCR (by prior arrangement only)</a>	Faeces (<5 days post-onset); other samples by arrangement. Minimum volume 200µL	Contact laboratory	Clinical samples: weekly	EVU
<a href="#">Genotyping of referred positive samples</a>	Faeces; other samples by prior arrangement. Minimum volume 200µL	Contact laboratory	Contact laboratory	EVU
<b>Sapovirus</b>				
<a href="#">RT-PCR (by prior arrangement only)</a>	Faeces (<5 days post-onset)	Contact laboratory	Contact laboratory	EVU
<b>SARS-CoV-1 and SARS CoV-2</b>				
Refer to coronavirus section on <a href="#">pages 16 to 17</a> Contact laboratory prior to collection of specimens for SARS-CoV-1				RVU
<b>Unknown haemadsorbing agents</b>				

Investigation	Sample required	Target turnaround time	Test schedule	Contact unit
	Tissue culture fluid	Contact laboratory	Contact laboratory	RVU
<b>Varicella-zoster virus (VZV)</b>				
<a href="#">IgG serology</a>	Serum (100µL)	21 days	Fortnightly	IDU
<a href="#">IgM serology</a>	Contact laboratory	Contact laboratory	Contact laboratory	IDU
<a href="#">Intrathecal antibody testing</a>	Paired serum and CSF (750µL each)	Contact laboratory	Contact laboratory	IDU
<a href="#">PCR / genotyping</a>	Vesicular fluid (200µL)	21 days	Twice per month	IDU
<b>Viral haemorrhagic fevers</b>				
<p>A 24-hour service is available for the urgent diagnosis of VHFs and smallpox through the Imported Fever Service (IFS). Hospital doctors can contact the IFS, after discussion with their local infection service consultant (microbiology, virology or infectious diseases), via 0844 778 8990.</p>				

## Referral (external) laboratories

### Samples

Referral laboratories where samples or subsamples are submitted for examination and/or data is submitted for analysis or interpretation. The UKAS accreditation status of referral laboratories is regularly checked.

<b>Investigation</b>	<b>Samples referred</b>	<b>Institution</b>	<b>Address</b>
Albumin and total IgG as part of intrathecal investigations	Serum and CSF	University Hospital Southampton NHS Foundation Trust	Department of Immunology Southampton General Hospital Tremona Road Southampton SO16 6YD United Kingdom

## Reports

Reports will be delivered electronically via E-lab, or will be printed and delivered by post if the referring laboratory is not registered to E-lab. For details on how to register for E-lab and further information, please email [LimsHelpdesk@ukhsa.gov.uk](mailto:LimsHelpdesk@ukhsa.gov.uk)

Please note reports will only be sent to the requestor named on the request form.

## Policy on emailing reports

The following guidelines have been prepared having taken into account the code of practice on reporting patients' results by email prepared by the Department of Health and Caldicott recommendations:

- it is UKHSA policy that reports containing patients' data should not be sent by email
- emails cannot be relied on to guarantee security of patients' data because they can be intercepted by a third party en route
- reports cannot be sent by fax – there are no fax facilities at UKHSA Colindale

## Quality assurance in VRD

### Referral site accreditation information

We receive many requests regarding the accreditation status of VRD. The laboratory is following accreditation to ISO 15189:2022. The following information may be of assistance: VRD is a UK Accreditation Services (UKAS) accredited medical laboratory No. 8825  
General information about our accreditation: [Quality Standards – Microbiology Services: Quality at laboratories of the UK Health Security Agency, Colindale.](#)

List of accredited services: see the schedule of accreditation on the [United Kingdom Accreditation Service \(UKAS\) website](#) (lab reference 8825:8825 Medical Single ([ukas.com](https://www.ukas.com)))  
For the most up to date information linked to services offered, contact the Quality Assurance Manager as indicated below. Lists of workflows with corresponding accreditation status are available upon request on a confidential basis.

External Quality Assurance and Proficiency Testing: All VRD laboratories participate in these where available and appropriate for the examination and interpretation of examination results. Any issues with EQA performance that could affect any of the services provided are communicated directly to service users where relevant.

Service updates: users will be informed in a timely manner of any delays beyond the published turnaround times where these could compromise patient care.

Issue of revised reports: any amendments to original reports will be highlighted to users.

Authorisation of reports: staff authorising reports are competency assessed, and, additionally, medical staff undergo revalidation to meet the professional standards set by the GMC.

The quality of our systems is also checked by our IQA schemes, which requires selection of referred samples for 'blinded' testing at a later date. After processing, the results for IQA samples are unblinded and are assessed against the results originally reported to the sending laboratory. Any discrepancies are fully investigated as to their root cause before remedial action is implemented. Results of our EQA and IQA performance are discussed at Quarterly Management Review meetings, and also at unit meetings, as appropriate.

Key contact for general quality-related enquiries:

Quality Assurance Manager, Virus Reference Department – Colindale

Sangita Sapkota (020 7811 7092)

Email: [sangita.sapkota@ukhsa.gov.uk](mailto:sangita.sapkota@ukhsa.gov.uk)

## Complaints

If there is a problem, or you are not satisfied with the service you have received, in the first instance contact the appropriate Unit Head. Contact details are given on the following pages against each unit, and in summary at the end of the user manual. Otherwise contact:

Quality Implementation and Compliance Manager, Public Health Microbiology Division

Dr Ifeoma Ekwueme (020 8327 7552)

email: [ifeoma.ekwueme@ukhsa.gov.uk](mailto:ifeoma.ekwueme@ukhsa.gov.uk)

or

Deputy Director, Public Health Microbiology Division

Dr Derren Ready (020 8327 6146)

email [derren.ready@ukhsa.gov.uk](mailto:derren.ready@ukhsa.gov.uk)

Complaints will be initially responded to within 5 working days and overall resolution within 20 days of notification. Resolution of complaints will be undertaken within the shortest timeframe achievable. If resolution cannot be achieved within 20 days, the complainant will be notified.

Our endeavour is to be responsive to the changing needs of all users of our services. We welcome comments on how we can improve the provision of these services. Please contact the department if you have any queries.

# Public Health Microbiology: recognition of Caldicott recommendations

The recommendations of the Caldicott Report (1997) and the subsequent Information Governance Review (2013) have been adopted by UK Health Security Agency and by the National Health Service as a whole. These recommendations relate to the security of patient identifying data (PID) and the uses to which it is put. Public Health Microbiology observes Caldicott guidance in handling PID and has appointed its own Caldicott Guardian. She advises the Director of the Virus Reference Department and others on confidentiality issues and is responsible for monitoring the physical security of PID in all parts of the Colindale site. This also applies to the transfer of results of investigations to and from the site whether by mail services or telephone.

Public Health Microbiology is keen to audit the security of its PID in collaboration with its customers. Customers are invited to review our arrangements in conjunction with individual laboratory directors and/or the Reference Caldicott Guardian. Customers are also asked to draw to the Reference Laboratories Caldicott Guardian's attention any instances where PID security has been threatened or has broken down. Uses that PID are put to outside clinical diagnostic services generally allow patient identifiers to have been removed beforehand, and when PID is used for research purposes the proposals are considered first by the UKHSA Research Ethics Committee. All enquiries about the security and use of PID at Public Health Microbiology should be addressed to the UKHSA Caldicott Guardian ([caldicott@ukhsa.gov.uk](mailto:caldicott@ukhsa.gov.uk)).

## Confidentiality

The laboratory shall be responsible, through legally enforceable agreements, for the management of all PID obtained or created during the performance of laboratory activities. Management of PID shall include privacy and confidentiality. Public Health Microbiology shall inform the customers in advance of the information it intends to place in the public domain. Except for information that the customers make publicly available, or when agreed between the Public Health Microbiology and the customers (for example for the purpose of responding to complaints), all other information is considered proprietary information and shall be regarded as confidential.

Results of laboratory examinations that have been anonymised may be used for such purposes as epidemiology, demography, or other statistical analyses, provided that all risks to patient privacy and confidentiality are mitigated and in accordance with any either legal or regulatory requirements, or both.

## Compliance with the Human Tissue Act: submitting tissue samples from deceased people

UKHSA Colindale is licensed by the Human Tissue Authority (licence number 12459) to store tissues from deceased people for scheduled purposes. Post-mortem samples are submitted by coroners or pathologists for examination to help them determine the cause of death.

Please note that consent is mandatory for all scheduled purposes. Samples taken from deceased persons that are sent to UKHSA Colindale for testing, where such testing is not related to determining the cause of death as directed by the coroner, will require appropriate consent from the deceased person or their relatives. For example, testing of post-mortem material for infectious agents following a needlestick injury sustained during the post-mortem will require consent. It is the obligation of the requesting clinician or pathologist to ensure that appropriate consent has been obtained.

Obtaining consent to remove, store and use human tissues for a scheduled purpose is one of the underlying principles of the Human Tissue Act. Public Health Microbiology receives post-mortem samples from coroners' post-mortems or from NHS establishments across the UK and therefore we are performing the examination under the authority of the coroner. Unless consent has been obtained or the coroner has requested that samples are retained for further testing, samples are disposed of within 3 months of the initial test being performed.

When tissue samples from deceased people are received at Public Health Microbiology they are retained securely and confidentiality is maintained in compliance with Caldicott principles, as are all samples received at this centre. It is normal practice for tissue samples from the deceased to be disposed of in the same way that all other clinical samples we receive are disposed of. However, we will adhere to any specific requirements regarding disposal or returning tissue samples if requested by the sending coroner or pathologist.

## Unit information

See also contact details on page 38 to 39.

### Antiviral Unit (AVU)

Head of Unit: Dr Tamyo Mbisa  
Tel: 020 8327 6099

The Antiviral Unit houses a WHO Global Specialised HIV Drug Resistance Laboratory.

The unit provides reference services for genotypic resistance testing of HIV and HCV (including minority mutant detection), analysis of HIV transmission events for public health-related investigations, HIV subtyping by sequencing and HSV antiviral resistance testing.

Other reference and training activities include organisation of UK external quality assessment (EQA) for HIV resistance testing, provision of training in laboratory and clinical aspects of HIV, HCV and HSV resistance testing, especially implementation of new assays, and leading the UK HIV genotypic resistance working group.

Research activities include development and roll-out of novel genotypic assays for detection of drug resistance in HIV, HCV and HSV (including next generation sequencing technologies), development and application of phenotypic assays for investigation of HIV drug resistance, investigation of the role of accessory mutations in levels of HIV drug resistance and viral fitness, and investigation of early events in HIV transmission.

### Blood Borne Viruses Unit (BBVU)

Unit Head: Dr Samreen Ijaz  
Tel: 020 8327 6554

The Blood Borne Virus Unit is engaged in research and development on Hepatitis Viruses and works closely with the Clinical Services Unit (CSU) at UKHSA Colindale and with the NHS Blood and Transplant Service (NHSBT).

Some of the work of the UKHSA Blood Borne Virus Unit is around improving blood safety. This is funded by NHSBT and members of the unit work closely with colleagues in the NHSBT UKHSA Epidemiology Unit.

The unit provides services for the molecular epidemiology of Hepatitis A, B, C and E transmission incidents and outbreaks, antiviral resistance testing for HBV, anti-HBc avidity



testing, screening for HBsAg, pre-core and BCP mutations, sequencing and phylogenetic analysis for Hepatitis A, B, C and E, and real-time HDV RNA and HEV RNA assays.

Surveillance activities include sequencing of acute HAV and HBV cases, and enhanced surveillance programmes for HAV, HBV and HEV. For details on the enhanced surveillance programmes, please contact the unit.

Research activities include epitope mapping of HBsAg variants including vaccine escape mutants, and blood safety studies in collaboration with NHSBT.

## Clinical Services Unit (CSU)

Unit Head: Dr Daniel Bradshaw  
Tel: 020 8327 6109

Scientific Lead: Dr Gary Murphy  
Tel: 020 8327 6935

Scientific Lead: Dr Siew-Lin Ngui  
Tel: 020 8327 6555

### Clinical enquiries

HIV, HTLV: Dr Daniel Bradshaw  
Tel: 020 8327 6109

Hepatitis Dr Siew-Lin Ngui  
Tel: 020 8327 6555

HHV-8: Dr Simon Carne  
Tel: 020 8327 6546

The unit provides diagnostic reference work relating to HIV-1 and HIV-2, Hepatitis viruses A, B, C, D and E, HTLV-I and -II, HHV-8, measles, mumps, rubella and parvovirus B19. A full list of services provided by the unit is shown in the 'Services available' section beginning on [page 16](#) of this manual. The laboratory provides high-throughput serological and molecular surveillance services. The unit is listed as a WHO pre-qualification evaluation laboratory.

## Enteric Viruses Unit (EVU)

Unit Head: Dr Cristina Celma

Tel: 020 8327 7846

The primary function of the national reference laboratory is to characterise non-polio enteroviruses, rotaviruses and noroviruses, to support national surveillance programmes and investigations of significant outbreaks. EVU can perform detection assays for specific enteric viruses, but only when detection assays are not offered by NHS and regional UKHSA Public Health Laboratories. EVU characterisation assays are not associated with specific turnaround times.

A comprehensive sequence database of characterised norovirus, sapovirus, astrovirus and rotavirus strains, including geographical and temporal distributions and the genetic diversity of co-circulating strains, has been established in collaboration with the Bioinformatics Unit. EVU collaborates with other UKHSA departments, NHS and academic institutions in the structured surveillance and study of enteric virus infections and the diseases they cause.

## High Containment Microbiology and Imaging department

The department provides diagnostic support for high consequence pathogens. A 24-hour service is available for the urgent diagnosis of VHFs and smallpox through the Imported Fever Service (IFS). Hospital doctors can contact the IFS, after discussion with their local infection service consultant (microbiology, virology or infectious diseases), via 0844 778 8990.

We have a modern ultrastructural imaging facility with a 120kV high-contrast, transmission electron microscope and a state-of-the-art laser scanning confocal microscope. The facility provides a diagnostic service to the NHS for orf and molluscum contagiosum viruses using negative stain EM. Referral is via the VRD General Office 020 83277887 (staffed 9am to 5pm Monday to Friday).

## Human Papillomavirus Unit

Unit Head: Dr Simon Beddows

Tel: 020 8327 6169

The unit contributes to national sexually transmitted infection surveillance programmes designed to monitor the impact of the HPV vaccines on the UK population. We also undertake studies to understand the immune responses generated following HPV vaccination and those generated during natural infection. The unit does not offer a diagnostic service for HPV infection.

## Immunisation and Diagnosis Unit (IDU)

Unit Head: Dr Keith Perry

Tel: 020 8327 6308

The unit provides diagnostic and reference services for measles, mumps, rubella, JC polyomavirus, parvovirus B19 (B19V), varicella-zoster virus (VZV), HHV6 and HHV7, and in collaboration with the Immunisation Department is responsible for the enhanced laboratory surveillance for measles, mumps and rubella infection in the UK. The laboratory also offers intrathecal antibody testing for investigation of meningoencephalitis.

The unit is a national and international reference centre for rash associated viral infections and the unit receives clinical samples and virus isolates from UKHSA, National Health Service and commercial laboratories across the UK and from overseas.

Services provided by the laboratory include reference serum and oral fluid antibody tests for rash illnesses, advice on management of rash outbreaks, investigation of adverse reactions following vaccination, and antigenic characterisation of measles, mumps, rubella and B19 infections.

In collaboration with CSU, the unit carries out oral fluid testing (for both antibody and RNA detection) for measles, mumps and rubella. Testing of samples obtained by this non-invasive method has greatly enhanced measles, mumps and rubella surveillance in the UK, and has been invaluable in tracking recent changes in measles epidemiology following the drop in MMR vaccine uptake in the UK due to unfounded doubts about vaccine safety.

The unit also provides advice on serological assay development, is involved in the development of near-patient tests, and provides monoclonal antibody generation and immunochemical modifications. For further information on these services, please contact the unit.

The unit is one of three WHO global Specialized Laboratories for Measles and Rubella (the other 2 are located in the USA and Japan). As such, it is responsible for the following services to laboratories within the global network:

- provision of technical advice and specialised training to regional and national laboratories
- provision of laboratory standards, training materials and quality control panels of sera and viruses
- organisation of periodic proficiency testing for regional laboratories
- evaluation and improvement of diagnostic kits and methods
- maintenance of the measles and rubella virus reference strain bank
- provision of viral sequencing and analysis on request

- administration and maintenance of the two WHO measles and rubella sequence databases (MeaNS and RubeNS, respectively)

## Polio Reference Service (PRS)

Head of Scientific Service: Dr Robin Gopal

Tel: 020 8327 6437

The Polio Reference Service (PRS) is the national WHO Global Poliovirus Network Laboratory and undertakes performs analyses to exclude polio virus infection using methodology specified by WHO as part of the global eradication programme. This includes virus isolation by specific cell culture, application of WHO molecular assays, and detection and quantification of anti-poliovirus neutralising antibodies.

The UK is committed to the Global Polio Eradication Initiative and has to conform to the poliovirus testing requirements set by the WHO Global Action Plan in compliance with WHO polio surveillance requirements. As such, it is essential that the correct sample types be submitted from all cases of suspected poliomyelitis and any case of acute flaccid paralysis/myelitis; further information can be found in the A to Z list of tests available, or by contacting PRS.

## Respiratory Virus Unit (RVU)

Head of Influenza and Respiratory Virology: Professor Maria Zambon

Tel: 020 8327 6810

RVU Unit Head: Dr Katja Hoschler

Tel: 020 8327 7002

The unit provides antigenic and genetic analysis of influenza isolates, and molecular detection, virus isolation in culture and serology tests for a range of respiratory viruses and investigation of outbreaks of respiratory virus infection. Genetic characterisation of respiratory viruses is undertaken, including whole genome sequencing of influenza viruses. Influenza antiviral susceptibility primary testing is performed as required, with genotypic and phenotypic characterisation of strains.

As a WHO National Influenza Laboratory, the unit undertakes:

- national surveillance of influenza and other respiratory viruses
- antigenic and genetic characterisation of circulating influenza strains
- data provided to WHO as evidence from the UK to guide the annual formulation of the influenza vaccine

- surveillance of antiviral susceptibility of influenza viruses derived from community and hospital sources, with monitoring achieved through genotypic and phenotypic analysis

The unit also contributes virological data (antigenic and genetic) to assist seasonal influenza vaccine effectiveness (VE) estimates, including assessment of the effectiveness of new vaccination programmes.

The work of RVU also involves the development of diagnostic tests for current and emerging respiratory viruses, and vaccine evaluation studies.

The unit is one of three WHO global RSV Reference Laboratories, and as such collaborates with WHO, providing technical support and advice to national laboratories.

The unit is also a WHO MERS CoV Reference Laboratory, providing confirmatory and reference services for MERS CoV, and a WHO Reference Laboratory for confirmatory testing for COVID-19.

## Contacts

Name	Designation	Email	Telephone
<b>Antiviral Unit (AVU)</b>			
Dr Tamyo Mbisa	Unit Head	<a href="mailto:tamyo.mbisa@ukhsa.gov.uk">tamyo.mbisa@ukhsa.gov.uk</a>	020 8327 6099
Dr John Poh	Technical Manager	<a href="mailto:John.poh@ukhsa.gov.uk">John.poh@ukhsa.gov.uk</a>	020 8327 6306
<b>Blood-borne Virus Unit (BBVU)</b>			
Dr Samreen Ijaz	Unit Head	<a href="mailto:samreen.ijaz@ukhsa.gov.uk">samreen.ijaz@ukhsa.gov.uk</a>	020 8327 6554
Dr John Poh	Technical Manager	<a href="mailto:John.poh@ukhsa.gov.uk">John.poh@ukhsa.gov.uk</a>	020 8327 6306
<b>Enteric Virus Unit (EVU)</b>			
Dr Cristina Celma	Unit Head	<a href="mailto:cristina.celma@ukhsa.gov.uk">cristina.celma@ukhsa.gov.uk</a>	020 8327 7846
Stuart Beard	Senior BMS	<a href="mailto:stuart.beard@ukhsa.gov.uk">stuart.beard@ukhsa.gov.uk</a>	020 8327 6225
Mihaela Cirdei	Technical Manager	<a href="mailto:mihaela.cirdei@ukhsa.gov.uk">mihaela.cirdei@ukhsa.gov.uk</a>	020 8327 6229
<b>HPV Unit</b>			
Dr Simon Beddows	Unit Head	<a href="mailto:simon.beddows@ukhsa.gov.uk">simon.beddows@ukhsa.gov.uk</a>	020 8327 6169
<b>Immunisation and Diagnosis Unit (IDU)</b>			
Dr Catherine Houlihan	Consultant Clinician	<a href="mailto:catherine.houlihan@ukhsa.gov.uk">catherine.houlihan@ukhsa.gov.uk</a>	01980612740
Dr Keith Perry	Unit Head	<a href="mailto:keith.perry@ukhsa.gov.uk">keith.perry@ukhsa.gov.uk</a>	020 83276308
Dr Jade Derrick	Clinical Scientist	<a href="mailto:jade.derrick@ukhsa.gov.uk">jade.derrick@ukhsa.gov.uk</a>	020 8327 7802

Name	Designation	Email	Telephone
Mihaela Cirdei	Technical Manager	<a href="mailto:mihaela.cirdei@ukhsa.gov.uk">mihaela.cirdei@ukhsa.gov.uk</a>	020 8327 6229
<b>Polio Reference Service (PRS)</b>			
Dr Robin Gopal	Head of Service	<a href="mailto:robin.gopal@ukhsa.gov.uk">robin.gopal@ukhsa.gov.uk</a>	020 8327 6437
Mihaela Cirdei	Technical Manager	<a href="mailto:mihaela.cirdei@ukhsa.gov.uk">mihaela.cirdei@ukhsa.gov.uk</a>	020 8327 6229
<b>Respiratory Virus Unit (RVU)</b>			
Prof. Maria Zambon	Head of Influenza and Respiratory Virology	<a href="mailto:maria.zambon@ukhsa.gov.uk">maria.zambon@ukhsa.gov.uk</a>	020 8327 6810
Dr Katja Hoschler	RVU Unit Head	<a href="mailto:katja.hoschler@ukhsa.gov.uk">katja.hoschler@ukhsa.gov.uk</a>	020 8327 7002
Janice Baldevarona	Technical Manager	<a href="mailto:janice.baldevarona@ukhsa.gov.uk">janice.baldevarona@ukhsa.gov.uk</a>	020 8327 6228
<b>Clinical Services Unit (CSU)</b>			
Dr Daniel Bradshaw	Unit Head	<a href="mailto:daniel.bradshaw@ukhsa.gov.uk">daniel.bradshaw@ukhsa.gov.uk</a>	020 8327 6019
Dr Gary Murphy	Scientific Lead	<a href="mailto:gary.murphy@ukhsa.gov.uk">gary.murphy@ukhsa.gov.uk</a>	020 8327 6935
Dr Siew Lin Ngui	Scientific Lead	<a href="mailto:siewlin.ngui@ukhsa.gov.uk">siewlin.ngui@ukhsa.gov.uk</a>	020 8327 6554
Dr Simon Carne	Clinical Scientist	<a href="mailto:simon.carne@ukhsa.gov.uk">simon.carne@ukhsa.gov.uk</a>	020 8327 6546
Shabnam Jamarani	Technical Manager	<a href="mailto:shabnam.jamarani@ukhsa.gov.uk">shabnam.jamarani@ukhsa.gov.uk</a>	020 8327 6939
<b>Advice on management of rabies exposure</b>			
	Rabies clerk	<a href="mailto:RIGS@ukhsa.gov.uk">RIGS@ukhsa.gov.uk</a>	0330 128 1020
<b>Quality (general queries, compliance and complaints)</b>			
Dr Ifeoma Ekwueme	Quality Implementation and Compliance Manager	<a href="mailto:ifeoma.ekwueme@ukhsa.gov.uk">ifeoma.ekwueme@ukhsa.gov.uk</a>	020 8327 7552
Sangita Sapkota	Quality Assurance Manager	<a href="mailto:sangita.sapkota@ukhsa.gov.uk">sangita.sapkota@ukhsa.gov.uk</a>	020 8327 6911
<b>VRD General Office</b>			
	Enquiries	<a href="mailto:vrqueries@ukhsa.gov.uk">vrqueries@ukhsa.gov.uk</a>	0208 327 7887

# About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

[UKHSA](#) is an executive agency, sponsored by the [Department of Health and Social Care](#).

© Crown copyright 2024  
Version 20

Prepared by: Dr Ifeoma Ekwueme  
For queries relating to this document, please contact: [ifeoma.ekwueme@ukhsa.gov.uk](mailto:ifeoma.ekwueme@ukhsa.gov.uk)

Published: August 2024  
Publication reference: GOV-15165



You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the UN  
Sustainable Development Goals

